Alpha Fetoprotein MS4 30294

AFP MS4

AFP MS4

AFP, unconjugated Estriol, hCG, Dimeric Inhibin A and Maternal Risk Interpretation

3 mL serum

1

Enter all patient information. Specimen should be drawn between 14-22.9 wks gestation

SST

R

Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days

Gross hemolysis • Gross lipemia

Set up: Mon-Sat; Report available: 3-4 days

Quad Screen results consistent with an increased risk of trisomy should be confirmed with amniotic fluid specimen. Results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.

See Laboratory Report

Maternal serum Quad Screen is used for prenatal screening of Down syndrome (Trisomy 21), Trisomy 18 (Edwards syndrome), and open neural tube defects (ONTD). This profile includes alpha-fetaprotein (AFP), unconjugated estriol (µE3), human chorionic gonadotropin (hCG), and inhibin A. Establishing risk for fetal Down syndrome, using the quad screen achieves a 70-75% detection rate with a 5% false positive rate. Screening for Trisomy 18 detects 60% of affected fetuses with a 0.2% false positive rate. MSAFP screening detects 88% of anencephaly and 79% of open spina bifida with a 3% false positive rate. Normal results do not ensure birth of a normal infant. In addition, 2-3% of newborns have some type of physical or mental defect, many of which may be undetectable with current prenatal diagnostic procedures.